Major role for ICDs (implantable cardioverter defibrillator) in reducing cardiac death
This article was originally published in Clinica
A significant US and Canadian trial has provided compelling evidence that patients with coronary artery disease (CAD) who are at risk of cardiac death would be better off receiving an implantable defibrillator rather than the commonly-used anti-arrhythmic drugs.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.